Lonza Group (LONN.SW) Stock Price
Lonza Group Price
Revenue has compounded at 5.7% per year over the past 19 years to 6.53 B CHF. Earnings per share have grown at 7.0% per year over the last 19 years. Lonza Group's net margin stands at 14.5%, down from 54.4% several years earlier. Lonza Group currently offers a dividend yield of about 0.35%. The payout ratio is around 15% of earnings. The dividend has grown at 2.7% per year over the past 19 years. Analysts set a median price target of 678.30 CHF, implying 18.2% above the current price. Of 31 analysts, 26 rate the stock a buy — an overall Buy consensus.
Lonza Group stock price
Lonza Group business model & stock analysis
Frequently asked questions about Lonza Group
The business model of Lonza Group AG is centered around providing customized and integrated solutions for the life sciences and specialty ingredients markets. Lonza operates through two main segments: Pharma & Biotech and Specialty Ingredients. In the Pharma & Biotech segment, Lonza offers contract development and manufacturing services for the pharmaceutical and biotechnology industries. This includes the development and production of active pharmaceutical ingredients and drug product manufacturing. The Specialty Ingredients segment focuses on providing high-quality ingredients and formulation solutions for various industries, including personal care, consumer health, and agro ingredients. Lonza Group AG aims to support its customers by delivering innovative and sustainable solutions in both segments.
Lonza Group AG is primarily active in the life sciences and specialty ingredients industries.
The main competitors of Lonza Group AG in the market include companies such as Merck KGaA, Thermo Fisher Scientific Inc., and Lonza's own subsidiary, Capsugel.
Lonza Group AG, a leading Swiss biotechnology and pharmaceutical company, has a rich history and background. Established in 1897 in Basel, Switzerland, Lonza has grown into a global powerhouse over the years. Originally a textile chemicals manufacturing firm, Lonza shifted its focus to life sciences in the early 20th century. The company specializes in providing advanced solutions and technologies for various industries, including healthcare, pharmaceuticals, and nutrition. Lonza Group AG is renowned for its expertise in cell and gene therapy, microbial control, and drug discovery. With a strong commitment to innovation, sustainability, and quality, Lonza continues to shape the future of healthcare and life sciences globally.
Lonza Group AG has achieved several significant milestones throughout its history. Some notable achievements include its establishment in 1897, its listing on the SIX Swiss Exchange in 1986, and its expansion into a global leader in life science and specialty ingredients. Lonza has gained recognition for its expertise in biopharmaceutical contract manufacturing and has successfully developed new innovative products and services. The company has also made strides in sustainability efforts, aiming to reduce its carbon emissions and environmental impact. Lonza continues to demonstrate its commitment to excellence and remains a leading player in the life science industry.
Lonza Group AG is primarily present in various countries and regions worldwide. The company has a global footprint and operates in several key markets, including but not limited to Switzerland, United States, Germany, Singapore, China, and United Kingdom. With its extensive international presence, Lonza Group AG leverages its expertise and capabilities to serve customers and deliver innovative solutions in the life sciences and specialty ingredients sectors. As a multinational corporation, Lonza Group AG's global reach allows it to capitalize on opportunities and meet the diverse needs of customers across different geographies.
Lonza Group AG is a prominent company that stands for strong values and a distinguished corporate philosophy. With a focus on delivering innovative solutions, Lonza prioritizes excellence, quality, and integrity in all its endeavors. The company strives to foster long-term partnerships while promoting sustainability and enhancing human health. By combining expertise in science and technology, Lonza creates value and supports customers in various industries worldwide. Moreover, as a responsible corporate entity, Lonza Group AG maintains a commitment to ethical practices, social responsibility, and environmental stewardship, ensuring that its operations align with the highest standards of corporate governance.
Analysts currently set an average price target of 680.23 CHF for the Lonza Group stock (median: 678.30 CHF), implying +18.5 % versus the latest price. The consensus is based on 31 analyst ratings.
31 analysts currently rate the Lonza Group stock: 26 recommend buying, 5 holding and 0 selling. For 2026, analysts expect Lonza Group to generate revenue of 7.12 B CHF and earnings per share of 18.22 CHF.
Converted at the current exchange rate, the Lonza Group share trades at 616.36 EUR (574.00 CHF).
The Lonza Group share (LONN.SW) is listed on 8 stock exchanges, including: London (0QNO.L), SIX (Zürich) (LONN.SW), Frankfurt (LO3.F), München (LO3.MU), Düsseldorf (LO3.DU), Hamburg (LO3.HM).
The Lonza Group AG is a leading company in the pharmaceutical, biotech, and specialty chemical industries. Its business model is based on the manufacturing and provision of solutions and services for its customers worldwide. The company is divided into three business segments: Pharma, Biotech, and Specialty Ingredients. Each segment serves different industries and customers and offers a wide range of products and services. The Pharma business segment offers a variety of products and services for pharmaceutical companies, including active ingredients, formulations, dosage forms, manufacturing processes, and biologics. Lonza's products and services are used by customers worldwide for the development and manufacturing of pharmaceuticals. The Biotech business segment offers solutions and services for the biotechnology industry, such as biotechnological active ingredients, cell therapies, and gene therapies. Lonza's customers use these products and services for the development of innovative therapies and medicines. The Specialty Ingredients business segment offers a comprehensive range of specialty chemicals and engineering services, including food additives, fragrances, flavors, and solutions for the aviation and electronics industries. Lonza's customers use these products and services to improve their products and provide their customers with unique and innovative solutions. Lonza also provides its customers with innovative technologies and capabilities to optimize their development and manufacturing processes. The company strives to provide its customers with comprehensive support to help them solve complex challenges in their industries. In addition to its products and services, Lonza works closely with its customers to offer customized solutions. The company ensures that its products and services meet the requirements of its customers and are continuously improved and developed. Lonza's business model is also based on sustainability. The company is committed to acting responsibly and sustainably to have a positive impact on the environment and society. This is reflected in how the company develops its product range and engages with the communities in which it operates. In summary, Lonza's business model is focused on the manufacturing and sale of products and services that meet the requirements of its customers. The company relies on innovative technologies and is committed to providing its customers with comprehensive support. Lonza also strives to promote and implement responsibility and sustainability in all aspects of its business model.
The expected revenue of Lonza Group is 7.12 B CHF. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Lonza Group is 1.28 B CHF. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Lonza Group is currently 31.50. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Lonza Group stock.
The price-to-sales ratio (P/S) of Lonza Group is currently 5.66. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Lonza Group stock.
The Eulerpool Quality Score for Lonza Group is 6/10.
The ISIN of Lonza Group is CH0013841017. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Lonza Group is 928619. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Lonza Group is LONN.SW. The ticker symbol is used to trade Lonza Group shares on the stock exchange.
Lonza Group stock
Lonza Group Peer Group
Lonza Group Ticker
Lonza Group FIGI
All fundamentals and in-depth analysis of Lonza Group
Our stock analysis for Lonza Group stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Lonza Group. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.